Dimon's Warning, Trump's Gamble, and the Inflation Trap Nobody's Ready For

Jamie Dimon doesn’t usually play Cassandra. The guy runs the biggest bank in America and tends to keep his doomcasting polite, wrapped in boardroom language. So when JPMorgan’s CEO raises an alarm about inflation destroying stock valuations, the market should probably listen instead of scrolling past it like another earnings note.

But here’s what’s actually happening: while Dimon’s warning about inflation sits in the headlines, traders are bidding up equities and crude oil on the back of Trump’s Iran diplomacy theater. One of these narratives is going to win. The other’s going to hurt.

A stall displaying Trump 2020 merchandise including shirts and signs at an outdoor market. Photo by Allen Beilschmidt sr. / Pexels

The Inflation Bomb Nobody Wants to Acknowledge

Dimon’s point is straightforward and terrifying if you actually think about it. Rising inflation doesn’t just squeeze corporate margins—it destroys the multiple expansion that’s propped up this entire rally. If inflation accelerates, the Fed has to stay higher for longer, which means the 17x P/E ratios we’ve gotten comfortable with start looking like a bad joke.

This isn’t theoretical. We lived through this movie in 2021-2022. The S&P 500 got demolished when the market realized inflation was sticky. We’re talking 35% peak-to-trough destruction. That’s not a correction. That’s a reallocation.

My read is Dimon’s worried about something specific: we’ve had three straight months of moderating inflation data, which lulled investors into thinking the battle’s won. It’s not. One supply shock—geopolitical disruption, wage pressures sticking around, commodity spikes—and the whole inflation thesis flips.

The irony? We might be about to create that shock ourselves.

Trump’s Hormuz Gamble Is Raising Oil

Crude prices jumped Monday on Trump’s tough posturing toward Iran around the Strait of Hormuz. About 20% of the world’s oil moves through that narrow corridor. A genuine disruption there doesn’t cost 5% on energy stocks. It costs way more across the entire economy.

Trump’s reportedly negotiating a 45-day ceasefire proposal with Iran and regional mediators. That’s actually diplomatic progress, which is good. But the messaging is pure theater: he’s talking about getting “tough” to secure a deal. Markets are pricing in a resolution that keeps oil stable. But if those negotiations collapse—and ceasefire talks involving the Middle East have a track record of collapsing—you’re looking at 20% of global oil supply getting squeezed.

That would send WTI to $90+ in about three weeks. Maybe higher. And suddenly Dimon’s inflation warning doesn’t sound paranoid anymore. It sounds prophetic.

Detailed close-up of a newspaper displaying global financial market statistics and country flags. Photo by Markus Spiske / Pexels

The Stock Winners Nobody’s Connecting

While the macro picture stays fuzzy, specific beneficiaries are already moving. Pfizer climbed to $28.30 and’s beating the S&P 500 by 9.4% over six months. Why? The Trump administration just green-lit Medicare Advantage payment increases—2.48% higher, more than $13 billion for 2027. That’s a direct subsidy to health insurers and pharma companies touching that ecosystem. Pfizer’s the obvious play here.

Hubbell is the outlier everyone should be watching. Up 157% over five years, 19.7% in the last six months, beating the S&P by 22%. That’s not multiple expansion anymore. That’s fundamental outperformance. The company’s hitting earnings targets and building momentum while the broader market treads water. That’s the kind of stock that actually survives an inflation shock because it’s pricing in tough conditions.

Then there’s Ulta. Down 5.2% over six months while the S&P is only down 2.3%. That’s underperformance you can’t ignore. Consumer discretionary stocks start dying first when inflation accelerates and the Fed keeps rates elevated. If I’m Dimon, that’s the chart I’m showing when I say “markets aren’t ready.”

Broadcom’s getting chip deals expanded with Google and Anthropic. That’s the opposite problem—too much euphoria around AI spending without any concern for the cost of capital if rates stay sticky. That deal looks good until the Fed has to raise again because inflation surprised to the upside.

Here’s What Worries Me Most

The Medicare Advantage news is genuinely constructive for health services. But it’s also the kind of policy signal that makes you wonder: who’s paying for this? If we’re expanding entitlements while managing Middle East tensions that could spike energy prices, we’re potentially setting ourselves up for stagflation. That’s the scenario where nothing works—not growth, not bonds, barely equities.

I’ll be honest: I don’t have perfect visibility here. Trump’s Iran negotiation could succeed and keep oil tame. If that happens, Dimon’s inflation warning gets punted another quarter and everyone cheers. But if it fails? If crude spikes and inflation data starts moving the wrong way in February or March? You’re going to see a massive rotation out of names like Ulta and into defensive plays like Hubbell and Pfizer.

The market’s acting like both things can be true at once—stable oil and multiple expansion. One of them’s getting repriced.